News

BioTelemetry, Inc. Acquires Sweden-based ADEA Medical AB and Expands International Service Offering

MALVERN, Pa., July 24, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that it has acquired ADEA Medical AB, an early-stage Swedish medical technology company that delivers remote health services in the Nordics. The acquisition is aligned with BioTelemetry’s longer-term strategy to increase its international footprint and offer its products and services to physicians and patients in the Nordics and other parts of Europe. BioTelemetry advances health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner. Through its BioTel Heart division, BioTelemetry processes over

BioTelemetry, Inc. to Release Second Quarter 2019 Earnings Results on July 30, 2019

MALVERN, Pa., July 19, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2019 earnings on Tuesday, July 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, July 30, 2019.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original

Telcare, a Division of BioTelemetry, Inc., Announces Collaboration with Onduo in Diabetes Management Program

Telcare, the manufacturer of the world’s first FDA-cleared cellular-enabled blood glucose monitor, has entered into a strategic collaboration with Onduo, a joint venture created by Verily (an Alphabet company) and Sanofi. Under this partnership, Telcare will serve as the supplier of remote blood glucose systems and the resulting data for patients enrolled in Onduo’s groundbreaking diabetes management program.

BioTelemetry Research and AMRA Raise the Standard for Medical Imaging in NASH/NAFLD Clinical Trials

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that BioTelemetry Research, their leading global imaging and cardiac core lab, and AMRA, the international leader in body composition analysis, have formed an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials.

BioTelemetry, Inc. to Release Second Quarter 2017 Earnings Results on August 8, 2017

BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2017 earnings on Tuesday, August 8 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, August 8, 2017. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.

BioTelemetry, Inc. Completes LifeWatch AG Acquisition

BioTelemetry, Inc. (NASDAQ:BEAT), announced today it has completed its acquisition of LifeWatch AG (SIX:LIFE). “We are gratified that LifeWatch AG shareholders embraced the immense strategic value and potential of this acquisition and moved quickly to support the BioTelemetry tender,” said Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc.